Available clinical data presented at the ASH Annual meeting finds P-BCMA-101 CAR-T therapy, targeting BCMA, can produce significant efficacy with low toxicity in patients with relapsed/refractory multiple myeloma.
Available clinical data presented at the ASH Annual meeting finds P-BCMA-101 CAR-T therapy, targeting BCMA, can produce significant efficacy with low toxicity in patients with relapsed/refractory multiple myeloma.
Available clinical data...